CDX 3379
Alternative Names: CDX-3379; KTN-3379Latest Information Update: 12 Apr 2023
Price :
$50 *
At a glance
- Originator MedImmune; Yale University
- Developer Celldex Therapeutics Inc; New York University School of Medicine
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; ERBB-3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Head and neck cancer; Malignant melanoma; Solid tumours; Thyroid cancer
Most Recent Events
- 03 Apr 2023 Celldex Therapeutics terminates a phase II trial in Head and neck cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA due to sponsor decision based on emerging risk-benefit profile (NCT03254927)
- 04 Mar 2021 Discontinued - Phase-I/II for Malignant melanoma (Combination therapy, In the elderly, Late-stage disease, In adults) in USA (IV) (Celldex pipeline, March 2021)
- 04 Mar 2021 Discontinued - Phase-II for Head and neck cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (IV) (Celldex pipeline, March 2021)